Hemodialysis without Systemic Anticoagulation: A Prospective Randomized Trial to Evaluate Five Strategies in Patients at High Risk of Bleeding

Pedro Henrique Franca Gois0 个研究点目标入组 200 人开始时间: 2019年3月13日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Individuals with end stage renal failure on maintenance HD or HDF for more than 3 months;
•In-centre dialysis; high risk of bleeding (at the discretion of the assisting renal physician);
•Native or graft arteriovenous fistula with blood flow at least 250 ml/min;
•Patients with a tunnelled catheter locked by heparin can be included in the study after removal of heparin and rinsing the catheter prior to starting the treatment;
•Minimum age of 18 years with no gender restriction.

•Dialysis in the intensive care unit;
•Patients with acute kidney injury;
•Patients treated in single needle mode;
•Known heparin contraindication (e.g. heparin-induced thrombocytopenia type II);
•Patients requiring blood products;
•Patients receiving oral anticoagulants (including anti-vitamin K) (> 3 days since treatment stopped and/or normalized international normalized ratio will be allowed);
•Patients receiving a combination of anti-platelet agents (> 5 days since treatment stopping will be allowed);
•Patients currently on unfractioned (UFH) or low molecular weight heparin (LMWH) for treatment of deep vein thrombosis;
•Patients treated with UFH or LMWH to prevent deep vein thrombosis (24 hours since last dose of LMWH or 12 hours since last dose of UFH was allowed).
•Patients with laboratory markers of liver dysfunction (ALT and AST more than double of upper borderline lab value);
•Patients with known coagulopathy or haemostasis disorder (pathological value of prothrombin time and aPTT, and platelets less than 50,000/ul);
•Patients with the diagnosis of malignancy.

发起方

Pedro Henrique Franca Gois